BioPorto
Manufacturing · Denmark · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Tuborg Havnevej St 15, Hellerup, Region ...Phone Number
+45 45290000Website
www.bioporto.comRevenue
$5.6 MillionStock Symbol
BIOPORIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About BioPorto
BioPorto specializes in developing diagnostic tools for acute kidney injury (AKI), with its flagship product being The NGAL Test, which enables early risk assessment in critically ill patients. The company also offers a range of NGAL biomarker products, including the FDA-cleared ProNephro AKI, aimed at pediatric AKI risk assessment. Their target clients include healthcare professionals and clinical researchers focused on improving kidney care and patient management. BioPorto is dedicated to transforming care through actionable biomarkers and advancing kidney health globally.Explore more
BioPorto Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioPorto your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioPorto has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on BioPorto recently announced quarterly report
BioPorto, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if BioPorto had a recent Job posting/layoffs
Product Launch: Get notified when BioPorto launches new products
Congratulate Masked Content for being promoted to Masked Content at BioPorto
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if BioPorto is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BioPorto has new funding data
Recommended Actions
Find VP level buyers at BioPorto
Find more new buyers
Company Profile Activity
Activity Insights
BioPorto is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioPorto is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioPorto.
BioPorto Tech Stack
A closer look at the technologies used by BioPorto
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Earnings
BioPorto has issued 2026 guidance for adjusted EBITDA of DKK 50 to 60 million.
Earnings, Financial Planning, Forecasting, Finance, Financial Strategy
Earnings
Earnings, Accounting, Financial Reporting, Finance
BioPorto News & Media
BioPorto initiates U.S. Adult Validation Study following U.S. Food and Drug Administration (FDA) feedback
June 9, 2026 Announcement no. 12BioPorto announces Interim Result for the First Quarter of 2026
May 21, 2026 Announcement no. 11
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioPorto
Sign Up For FreeTo access detailed company insights
BioPorto specializes in developing diagnostic tools for acute kidney injury (AKI), with its flagship product being The NGAL Test, which enables early risk assessment in critically ill patients. The company also offers a range of NGAL biomarker products, including the FDA-cleared ProNephro AKI, aimed at pediatric AKI risk assessment. Their target cl... Read More
